Skip to main content

Articles

Page 1 of 13

  1. The evolutionarily conserved protein FBXO9 acts as a substrate receptor for the SKP1-cullin-1-RBX1 ubiquitin ligase and is implicated in cancer, exhibiting either tumor-suppressive or oncogenic effects dependi...

    Authors: Liang Liu, Xiaodong Chen, Leilei Wu, Kaizong Huang, Zhenyi Wang, Yaolin Zheng, Cheng Zheng, Zhenshan Zhang, Jiayan Chen, Jiaming Wei, Song Chen, Weilin Jin, Jinfei Chen, Dongping Wei and Yaping Xu
    Citation: Experimental Hematology & Oncology 2024 13:32
  2. Sarcoma is a malignant tumor that originates from mesenchymal tissue. The common treatment for sarcoma is surgery supplemented with radiotherapy and chemotherapy. However, patients have a 5-year survival rate ...

    Authors: Jing Zeng, Xianghong Zhang, Zhengjun Lin, Yu Zhang, Jing Yang, Pengcheng Dou and Tang Liu
    Citation: Experimental Hematology & Oncology 2024 13:31
  3. A-to-I RNA editing is an abundant post-transcriptional modification event in hepatocellular carcinoma (HCC). Evidence suggests that adenosine deaminases acting on RNA 1 (ADAR1) correlates to oxidative stress t...

    Authors: Houhong Wang, Xiaoyu Wei, Lu Liu, Junfeng Zhang and Heng Li
    Citation: Experimental Hematology & Oncology 2024 13:30
  4. Mesenchymal stem cells (MSCs) possess multipotent properties that make them promising candidates for immunomodulation and regenerative medicine. However, MSC heterogeneity poses challenges to their research re...

    Authors: Miao Yu, Ke Sui, Zheng Wang and Xi Zhang
    Citation: Experimental Hematology & Oncology 2024 13:29
  5. Although the efficacy of chimeric antigen receptor (CAR)-T cell therapy has been widely demonstrated, its clinical application is hampered by the complexity and fatality of its side effe...

    Authors: Linqin Wang, Yuqi Lv, Linghui Zhou, Shenghao Wu, Yuanyuan Zhu, Shan Fu, Shuyi Ding, Ruimin Hong, Mingming Zhang, Hanjing Yu, Alex H. Chang, Guoqing Wei, Yongxian Hu and He Huang
    Citation: Experimental Hematology & Oncology 2024 13:28
  6. Acute myeloid leukemia (AML) is a highly aggressive hematologic cancer with poor survival across a broad range of molecular subtypes. Development of efficacious and well-tolerable therapies encompassing the ra...

    Authors: Alexander R. Marr, Madeline Halpin, Dominique L. Corbin, Yerdanos Asemelash, Steven Sher, Britten K. Gordon, Ethan C. Whipp, Shaneice Mitchell, Bonnie K. Harrington, Shelley Orwick, Samon Benrashid, Virginia M. Goettl, Vedat Yildiz, Andrew D. Mitchell, Olivia Cahn, Alice S. Mims…
    Citation: Experimental Hematology & Oncology 2024 13:27
  7. A drug conjugate consists of a cytotoxic drug bound via a linker to a targeted ligand, allowing the targeted delivery of the drug to one or more tumor sites. This approach simultaneously reduces drug toxicity ...

    Authors: Ling Zhou, Yunlong Lu, Wei Liu, Shanglong Wang, Lingling Wang, Pengdou Zheng, Guisha Zi, Huiguo Liu, Wukun Liu and Shuang Wei
    Citation: Experimental Hematology & Oncology 2024 13:26
  8. Over the past few years, dual-targeted chimeric antigen receptor (CAR) T-cell therapy has been employed in the management of hematological malignancies to mitigate treatment failure, particularly in cases of a...

    Authors: Jingyi Yang, Hao Guo, Lu Han, Yongping Song and Keshu Zhou
    Citation: Experimental Hematology & Oncology 2024 13:25
  9. Transcription factor GATA1 controls the delicate balance between proliferation, differentiation and apoptosis in both the erythroid and megakaryocytic lineages. In addition to full-length GATA1, there is an GA...

    Authors: Daishi Ishihara, Atsushi Hasegawa, Ikuo Hirano, James Douglas Engel, Masayuki Yamamoto and Ritsuko Shimizu
    Citation: Experimental Hematology & Oncology 2024 13:24
  10. GATA1 plays a critical role in differentiation, proliferation, and apoptosis during erythropoiesis. We developed a Gata1 knock-down allele (Gata1.05) that results in GATA1 expression at 5% of endogenous level. In...

    Authors: Ikuo Hirano, Kanako Abe, James Douglas Engel, Masayuki Yamamoto and Ritsuko Shimizu
    Citation: Experimental Hematology & Oncology 2024 13:23
  11. Hepatocellular carcinoma (HCC) is closely associatedwith chronic liver diseases, particularly liver cirrhosis, which has an altered extracellular matrix (ECM) composition. The influence and its mechanism of th...

    Authors: Xiao-Tian Shen, Sun-Zhe Xie, Xin Zheng, Tian-Tian Zou, Bei-Yuan Hu, Jing Xu, Lu Liu, Yun-Feng Xu, Xu-Feng Wang, Hao Wang, Shun Wang, Le Zhu, Kang-Kang Yu, Wen-Wei Zhu, Lu Lu, Ju-Bo Zhang…
    Citation: Experimental Hematology & Oncology 2024 13:20
  12. Ferroptosis is a new form of nonapoptotic and iron-dependent type of cell death. Glutathione peroxidase-4 (GPX4) plays an essential role in anti-ferroptosis by reducing lipid peroxidation. Although acute myelo...

    Authors: Shuya Feng, Yigang Yuan, Zihan Lin, Min Li, Daijiao Ye, Liuzhi Shi, Danyang Li, Min Zhao, Chen Meng, Xiaofei He, Shanshan Wu, Fang Xiong, Siyu Ye, Junjun Yang, Haifeng Zhuang, Lili Hong…
    Citation: Experimental Hematology & Oncology 2024 13:19
  13. Mixed-lineage leukemia (MLL) fusion gene caused by chromosomal rearrangement is a dominant oncogenic driver in leukemia. Due to having diverse MLL rearrangements and complex characteristics, MLL leukemia treated ...

    Authors: Tian-Qi Chen, Heng-Jing Huang, Shun-Xin Zhu, Xiao-Tong Chen, Ke-Jia Pu, Dan Wang, Yan An, Jun-Yi Lian, Yu-Meng Sun, Yue-Qin Chen and Wen-Tao Wang
    Citation: Experimental Hematology & Oncology 2024 13:18
  14. Patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) often exhibit limited responses to traditional chemotherapy, resulting in poor prognosis. The combination of venet...

    Authors: Xubo Gong, Xin He, Lin Wang, Teng Yu, Weiwei Liu, Huiying Xu, Lan Jin, Xiang Li, Bin Zhang, Zhihua Tao and Wenbin Qian
    Citation: Experimental Hematology & Oncology 2024 13:17
  15. The 2022 European LeukemiaNet (ELN) updated the previous risk classification published in 2017 but the prognostic significance for allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains unclear...

    Authors: Haixiao Zhang, Xinhui Zheng, Wenwen Guo, Yonghui Xia, Rongli Zhang, Weihua Zhai, Xin Chen, Qiaoling Ma, Donglin Yang, Jialin Wei, Aiming Pang, Yi He, Sizhou Feng, Jianxiang Wang, Mingzhe Han and Erlie Jiang
    Citation: Experimental Hematology & Oncology 2024 13:16
  16. Lung adenocarcinoma (LUAD) is the leading cause of cancer-related death globally. Although the gut microbiota's role in the antitumor efficacy of many cancers has been revealed, its involvement in the response...

    Authors: Ting Jiang, Meng Zhang, Shaoyu Hao, Shi Huang, Xin Zheng and Zheng Sun
    Citation: Experimental Hematology & Oncology 2024 13:15
  17. Brexucabtagene autoleucel CAR-T therapy is highly efficacious in overcoming resistance to Bruton’s tyrosine kinase inhibitors (BTKi) in mantle cell lymphoma. However, many patients relapse post CAR-T therapy w...

    Authors: Fangfang Yan, Vivian Jiang, Alexa Jordan, Yuxuan Che, Yang Liu, Qingsong Cai, Yu Xue, Yijing Li, Joseph McIntosh, Zhihong Chen, Jovanny Vargas, Lei Nie, Yixin Yao, Heng-Huan Lee, Wei Wang, JohnNelson R. Bigcal…
    Citation: Experimental Hematology & Oncology 2024 13:14
  18. Glioblastoma multiforme (GBM) stands as a formidable challenge in oncology because of its aggressive nature and severely limited treatment options. Despite decades of research, the survival rates for GBM remai...

    Authors: Charles H. Williams, Leif R. Neitzel, Jessica Cornell, Samantha Rea, Ian Mills, Maya S. Silver, Jovanni D. Ahmad, Konstantin G. Birukov, Anna Birukova, Henry Brem, Betty Tyler, Eli E. Bar and Charles C. Hong
    Citation: Experimental Hematology & Oncology 2024 13:13
  19. Leukemias are refractory hematological malignancies, characterized by marked intrinsic heterogeneity which poses significant obstacles to effective treatment. However, traditional bulk sequencing techniques ha...

    Authors: Jianche Liu, Penglei Jiang, Zezhen Lu, Zebin Yu and Pengxu Qian
    Citation: Experimental Hematology & Oncology 2024 13:12
  20. KRAS mutation is one of the most common oncogenic drivers in NSCLC, however, the response to immunotherapy is heterogeneous owing to the distinct co-occurring genomic alterations. KRAS/LKB1 co-mutated lung adenoc...

    Authors: Meng Qiao, Fei Zhou, Xinyu Liu, Tao Jiang, Haowei Wang, Xuefei Li, Chao Zhao, Lei Cheng, Xiaoxia Chen, Shengxiang Ren, Zaiqi Wang and Caicun Zhou
    Citation: Experimental Hematology & Oncology 2024 13:11
  21. Metabolic reprogramming is an emerging hallmark of cancer cells, enabling them to meet increased nutrient and energy demands while withstanding the challenging microenvironment. Cancer cells can switch their m...

    Authors: Jianqiang Yang, Chloe Shay, Nabil F. Saba and Yong Teng
    Citation: Experimental Hematology & Oncology 2024 13:10
  22. t(8;21)(q22;q22) is one of the most frequent chromosomal abnormalities in acute myeloid leukemia (AML), leading to the generation of the fusion protein AML1-ETO. Despite t(8;21) AML being considered as a subty...

    Authors: Wei Zhou, Siying Li, Hong Wang, Jingfeng Zhou, Shuyi Li, Guofeng Chen, Wei Guan, Xianli Fu, Clara Nervi, Li Yu and Yonghui Li
    Citation: Experimental Hematology & Oncology 2024 13:9
  23. RNA modifications have been proven to play fundamental roles in regulating cellular biology process. Recently, maladjusted N7-methylguanosine (m7G) modification and its modifiers METTL1/WDR4 have been confirmed a...

    Authors: Pan Zhao, Lin Xia, Dan Chen, Wei Xu, Huanping Guo, Yinying Xu, Bingbing Yan, Xiao Wu, Yuxia Li, Yunfang Zhang and Xi Zhang
    Citation: Experimental Hematology & Oncology 2024 13:8
  24. Cancer immunotherapy has emerged as a promising strategy in the treatment of colorectal cancer, and relapse after tumor immunotherapy has attracted increasing attention. Cancer stem cells (CSCs), a small subse...

    Authors: Qi Zhao, Hong Zong, Pingping Zhu, Chang Su, Wenxue Tang, Zhenzhen Chen and Shuiling Jin
    Citation: Experimental Hematology & Oncology 2024 13:6
  25. Hepatocellular carcinoma (HCC) is one of the most common malignancies with a high lethality rate. ZMIZ2 is a transcriptional co-activator implicated in various human diseases. However, the role and molecular m...

    Authors: Yang Ding, Yumei Ning, Hui Kang, Yuan Yuan, Kun Lin, Chun Wang, Yun Yi, Jianghua He, Lurao Li, Xingxing He and Ying Chang
    Citation: Experimental Hematology & Oncology 2024 13:5
  26. From October 2017 to June 2022, we retrospectively report outcomes of R/R DLBCL patients with failure of CAR-T therapy, then receiving allo-HSCT. Among 10 patients, 5 were males and 5 females, with a median ag...

    Authors: Mengya Cong, Sicheng Ai, Liqing Kang, Mao Jin, Ying Zhu, Caixia Li, Zhengming Jin, Lei Yu, Depei Wu and Haiwen Huang
    Citation: Experimental Hematology & Oncology 2024 13:4
  27. As integral components of the immune microenvironment, tissue resident macrophages (TRMs) represent a self-renewing and long-lived cell population that plays crucial roles in maintaining homeostasis, promoting...

    Authors: Minmin Cao, Zihao Wang, Wanying Lan, Binghua Xiang, Wenjun Liao, Jie Zhou, Xiaomeng Liu, Yiling Wang, Shichuan Zhang, Shun Lu, Jinyi Lang and Yue Zhao
    Citation: Experimental Hematology & Oncology 2024 13:3
  28. Biliary tract cancers (BTCs) are heterogeneous malignancies with dismal prognosis due to tumor aggressiveness and poor response to limited current therapeutic options. Tumor exome profiling has allowed to succ...

    Authors: Clémence Astier, Carine Ngo, Léo Colmet-Daage, Virginie Marty, Olivia Bawa, Claudio Nicotra, Maud Ngo-Camus, Antoine Italiano, Christophe Massard, Jean-Yves Scoazec, Cristina Smolenschi, Michel Ducreux, Antoine Hollebecque and Sophie Postel-Vinay
    Citation: Experimental Hematology & Oncology 2024 13:2
  29. The use of central nervous system (CNS) prophylaxis for patients with diffuse large B-cell lymphoma (DLBCL) remains controversial. Although uncommon, CNS relapses are invariably fatal in this otherwise curable...

    Authors: Bernard Ji Guang Chua, Chen Ee Low, Chun En Yau, Ya Hwee Tan, Jianbang Chiang, Esther Wei Yin Chang, Jason Yongsheng Chan, Eileen Yi Ling Poon, Nagavalli Somasundaram, Mohamed Farid Bin Harunal Rashid, Miriam Tao, Soon Thye Lim and Valerie Shiwen Yang
    Citation: Experimental Hematology & Oncology 2024 13:1
  30. KRASG12C inhibitors (KRASG12Ci) AMG510 and MRTX849 have shown promising efficacy in clinical trials and been approved for the treatment of KRASG12C-mutant cancers. However, the emergence of therapy-related drug r...

    Authors: Yafang Wang, Mingyue Yao, Cheng Li, Kexin Yang, Xiaolong Qin, Lansong Xu, Shangxuan Shi, Chengcheng Yu, Xiangjun Meng and Chengying Xie
    Citation: Experimental Hematology & Oncology 2023 12:105
  31. Triple-Negative Breast Cancer is particularly aggressive, and its metastasis to the brain has a significant psychological impact on patients' quality of life, in addition to reducing survival. The development ...

    Authors: Julien Cicero, Sarah Trouvilliez, Martine Palma, Gaetan Ternier, Laurine Decoster, Eloise Happernegg, Nicolas Barois, Alexandre Van Outryve, Lucie Dehouck, Roland P. Bourette, Eric Adriaenssens, Chann Lagadec, Cagatay Mehmet Tarhan, Dominique Collard, Zied Souguir, Elodie Vandenhaute…
    Citation: Experimental Hematology & Oncology 2023 12:104
  32. Pyroptosis, an inflammatory programmed cell death, distinguishes itself from apoptosis and necroptosis and has drawn increasing attention. Recent studies have revealed a correlation between the expression leve...

    Authors: Mengyuan Li, Ping Jiang, Yuhan Yang, Liting Xiong, Shuhua Wei, Junjie Wang and Chunxiao Li
    Citation: Experimental Hematology & Oncology 2023 12:103
  33. Pseudomyxoma peritonei (PMP) is a rare disease characterized by a massive accumulation of mucus in the peritoneal cavity. The only effective treatment is aggressive surgery, aimed at removing all visible tumor...

    Authors: Mari C. Vázquez-Borrego, Melissa Granados-Rodríguez, Florina I. Bura, Ana Martínez-López, Blanca Rufián-Andújar, Francisca Valenzuela-Molina, Lidia Rodríguez-Ortiz, Sergio Haro-Yuste, Ana Moreno-Serrano, Rosa Ortega-Salas, Rafael Pineda-Reyes, Carmen Michán, José Alhama, Antonio Romero-Ruiz and Álvaro Arjona-Sánchez
    Citation: Experimental Hematology & Oncology 2023 12:102
  34. Differentiating between pancreatic ductal adenocarcinoma (PDAC) and cholangiocarcinoma (CCA) is crucial for the appropriate course of treatment, especially with advancements in the role of neoadjuvant chemothe...

    Authors: Mireia Mato Prado, Jisce R. Puik, Leandro Castellano, Elena López-Jiménez, Daniel S. K. Liu, Laura L. Meijer, Tessa Y. S. Le Large, Eleanor Rees, Niccola Funel, Shivan Sivakumar, Stephen P. Pereira, Geert Kazemier, Babs M. Zonderhuis, Joris I. Erdmann, Rutger-Jan Swijnenburg, Andrea Frilling…
    Citation: Experimental Hematology & Oncology 2023 12:101
  35. Cyclic-dependent kinase (CDK) 4/6 kinases, as the critical drivers of the cell cycle, are involved in the tumor progression of various malignancies. Pharmacologic inhibitors of CDK4/6 have shown significant cl...

    Authors: Chuntao Quan, Zhijie Wu, Juan Xiong, Manqing Li, Yu Fu, Jiaying Su, Yue Wang, Lvwen Ning, Deju Zhang and Ni Xie
    Citation: Experimental Hematology & Oncology 2023 12:100
  36. Multiple myeloma (MM) is related to immune disorders, recent studys have revealed that immunotherapy can greatly benefit MM patients. Immune checkpoints can negatively modulate the immune system and are closel...

    Authors: Zhaoyun Liu, Xintong Xu, Hui Liu, Xianghong Zhao, Chun Yang and Rong Fu
    Citation: Experimental Hematology & Oncology 2023 12:99
  37. Natural killer (NK) cells are promising alternatives for the production of “off-the-shelf” CAR products, posing a lower risk of cytokine release syndrome (CRS) than CAR-T cells. We synthesized four single VHH-...

    Authors: Quan Ren, Yingling Zu, Hongchang Su, Qiumei Lu, Bin Xiang, Yanping Luo, Jishuai Zhang and Yongping Song
    Citation: Experimental Hematology & Oncology 2023 12:98
  38. Dendritic cells (DCs) serve as a pivotal link connecting innate and adaptive immunity by processing tumor-derived antigens and activating T cells. The advent of single-cell sequencing has revolutionized the ca...

    Authors: Qingyu Huang, Fuhao Wang, Di Hao, Xinyu Li, Xiaohui Li, Tianyu Lei, Jinbo Yue and Chao Liu
    Citation: Experimental Hematology & Oncology 2023 12:97
  39. Being stimulated by the chemokine CXCL12, the CXCR4 / CXCR7 cascade is involved in tumor proliferation, migration, and metastasis. The interaction between CXCL12, secreted by cells from the microenvironment, a...

    Authors: Gamal A. Wakileh, Philipp Bierholz, Mara Kotthoff, Margaretha A. Skowron, Felix Bremmer, Alexa Stephan, Stephanie M. Anbuhl, Raimond Heukers, Martine J. Smit, Philipp Ströbel and Daniel Nettersheim
    Citation: Experimental Hematology & Oncology 2023 12:96
  40. Recurrence is one of the main causes of treatment failure in early-stage non-small cell lung cancer (NSCLC). However, there are no predictors of the recurrence of early-stage NSCLC, and the molecular mechanism...

    Authors: Hao Luo, Qing Li, Ren-Tao Wang, Liang Zhang, Wei Zhang, Meng-Sheng Deng, Yuan-Yuan Luo, Xintong Ji, Yongheng Wen, Xuan-Rui Zhou, Bo Xu, Dong Wang, Bin Hu, Hua Jin and Cheng-Xiong Xu
    Citation: Experimental Hematology & Oncology 2023 12:94
  41. Targeted therapy with Bruton tyrosine kinase (BTK) inhibitors have revolutionized the treatment of patients with various B-cell malignancies. BTK inhibitors such as ibrutinib, zanubrutinib, orelabrutinib, and ...

    Authors: Yuqin Song, Shang-Ju Wu, Zhixiang Shen, Donglu Zhao, Thomas Sau Yan Chan, Huiqiang Huang, Lugui Qiu, Jianyong Li, Tran-der Tan, Jun Zhu, Yongping Song, Wei-Han Huang, Weili Zhao, Herman Sung Yu Liu, Wei Xu, Naizhi Chen…
    Citation: Experimental Hematology & Oncology 2023 12:92
  42. Circular RNAs (circRNAs) are a class of covalently closed, endogenous ncRNAs. Most circRNAs are derived from exonic or intronic sequences by precursor RNA back-splicing. Advanced high-throughput RNA sequencing...

    Authors: Xin-Yi Feng, Shun-Xin Zhu, Ke-Jia Pu, Heng-Jing Huang, Yue-Qin Chen and Wen-Tao Wang
    Citation: Experimental Hematology & Oncology 2023 12:91
  43. CD19-targeted chimeric receptor antigen (CAR)-T cell therapy has shown remarkable clinical efficacy in the treatment of relapsed or refractory (R/R) B-cell malignancies. However, 30%–60% of patients eventually...

    Authors: Jia Xu, Wenjing Luo, Chenggong Li and Heng Mei
    Citation: Experimental Hematology & Oncology 2023 12:90
  44. Impaired neutrophil activity is an important issue in chronic lymphocytic leukemia (CLL), as it contributes to a dysfunctional immune response leading to life-threatening infections in patients. Some features ...

    Authors: Agnieszka Goral, Marta Sledz, Aneta Manda-Handzlik, Adrianna Cieloch, Alicja Wojciechowska, Mieszko Lachota, Agnieszka Mroczek, Urszula Demkow, Radoslaw Zagozdzon, Katarzyna Matusik, Malgorzata Wachowska and Angelika Muchowicz
    Citation: Experimental Hematology & Oncology 2023 12:89
  45. CAR T cell therapy has been successfully used in the treatment of hematological malignancies, and the strategy that deletion of inhibitory receptor on the CAR T cell surface, such as PD-1, greatly enhance the ...

    Authors: Ming Liu, Linlin Zhang, Mingtian Zhong, Yihao Long, Wenhui Yang, Ting Liu, Xingxu Huang and Xiaodong Ma
    Citation: Experimental Hematology & Oncology 2023 12:88

Annual Journal Metrics

  • 2022 Citation Impact
    11.4 - 2-year Impact Factor
    7.3 - 5-year Impact Factor
    1.609 - SNIP (Source Normalized Impact per Paper)
    1.908 - SJR (SCImago Journal Rank)

    2023 Speed
    4 days submission to first editorial decision for all manuscripts (Median)
    100 days submission to accept (Median)

    2023 Usage
    696,150 downloads
    375 Altmetric mentions